IL-100 is considered a potent anti-inflammatory cytokine, that strongly inhibits the productionn of proinflammatory cytokines. Recent studies have suggested that IL-10 also hass immunostimulatory properties on CD4+, CD8+ T cells and/or NK cells, resulting in increasedd IFN-y production. To determine the effect of IL-10 on IFN-y production and relatedd inflammatory responses in humans, 16 healthy subjects received a bolus i.v. injectionn of LPS (4 ng/kg) in combination with either placebo or recombinant human IL-10 (255 ug/kg), administered just prior to or 1 h after LPS. IL-10 treatment, particularly when administeredd after LPS, enhanced LPS-induced IFN-y release, as well as the release of the IFN-y-dependentt chemokines IFN-y-inducible protein-10 and monokine induced by IFN-y, whilee inhibiting or not influencing the production of IFN-y-inducing cytokines. In addition, IL-100 treatment enhanced activation of CTL's and NK cells after LPS injection, as reflected byy increased levels of soluble granzymes. These data indicate that high dose IL-10 treatmentt in patients with inflammatory disorders can be associated with undesired proinflammatoryy effects.
Introduction n
IL-100 is a non-covalently linked homodimeric cytokine that is produced by a large variety off cells including monocytes/macrophages, B and T lymphocytes, and NK cells (1,2). IL-100 has many anti-inflammatory and immunosuppressive activities. In vitro, IL-10 downregulatess monocyte macrophage effector functions including antigen-presenting capacityy and the production of cytokines such as TNF, IL-lp, IL-6, IL-8 and IL-12 (3, 4) . IL-100 also inhibits T cell proliferation and cytokine production (5) . In mice, IL-10 protects againstt lethality during endotoxemia and staphylococcal enterotoxin B (SEB)-induced shockk (6) (7) (8) . In addition, IL-10 treatment inhibits the activation of the cytokine network duringg experimental endotoxemia in primates (9) and humans (10) .
Recently,, it has been suggested that IL-10 has immunostimulatory properties. In vitro, IL-100 stimulates proliferation and differentiation of activated human B cells (11) , and preincubationn of resting CD4+ lymphocytes with IL-10 enhances their capacity to produce cytokiness after activation (12) . Moreover, IL-10 enhances IL-2-driven proliferation of preactivatedd human purified CD8+ T cells (13) . Addition of IL-10 to mouse splenic NK celll cultures stimulated with IL-12 and IL-18 results in enhanced IFN-y production (14) . In mice,, IL-10 injections accelerated graft-versus-host disease and graft rejection in bone marroww recipients, probably mediated by augmented IFN-y production by T cells (15) .
Thesee data indicate that under certain conditions, IL-10 can have stimulatory effects on CD4+,, CD 8+ T cells and/or NK cells, which may result in increased IFN-y production. Knowledgee of potential proinflammatory effects of IL-10 in humans in vivo is highly limited.. Such knowledge is important, since IL-10 has been advocated as a new treatment modalityy for several diseases, including Crohn's disease and rheumatoid arthritis (16, 17) . Therefore,, we studied the effect of IL-10 on IFN-y production and related inflammatory responsess during human endotoxemia, a well accepted model of systemic inflammation in humans. .
Materialss and methods

Studyy design
Thiss study was performed simultaneously with investigations on the effects of recombinant humann (rh)IL-lO on cytokine production, leukocytes and the hemostatic mechanism, the resultss of which have been reported elsewhere (10, 18) . A total of 16 healthy volunteers (meann 23, range 20-35 years) participated in a double-blind, cross-over, randomized, placebo-controlledd study. Written informed consent was obtained from all study participants.. The study was approved by the research and ethical committees of the Academicc Medical Center. Medical history, physical and routine laboratory examination, chestt X-ray and electrocardiogram of all volunteers were normal. Each volunteer was studiedd on 2 occasions after endotoxin (LPS) injection, separated by a wash-out period of 6 weeks;; on one occasion in combination with placebo, on the other occasion in combination withh rhIL-10. The participants were randomized into 2 groups of 8 persons. Group 1 receivedd placebo or rhIL-10 treatment 2 minutes prior to LPS, group 2 received placebo or rhIL-100 1 hour after LPS administration.
RhIL-100 (Schering-Plough Research Institute, Kenilworth, NJ) was supplied as a sterile powder,, and reconstituted with sterile water. RhIL-10 was administered by intravenous injectionn at a dose of 25 ug/kg. The reconstituted placebo powder was identical in appearancee and was administered in an identical manner. The LPS preparation, LPS referencee standard lot G, E. coli (United States Pharmacopeia Convention Inc., Rockville, MD)) was administered at a dose of 4 ng/kg over 1 minute in an ante-cubital vein, contralaterall to the site of rhIL-10.
Bloodd samples were drawn directly before LPS injection and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 88 and 12 h thereafter. Blood was collected in non-additive vacutainer tubes (Becton Dickinson,, Mountain View, CA); after clotting samples were centrifuged at 2000 x g for 20 minutess at room temperature and serum was stored at -70°C until assays were performed.
Wholee blood stimulation
Inn separate experiments, whole blood was collected aseptically from 6 healthy donors using aa sterile collecting system consisting of a butterfly needle connected to a syringe (Becton Dickinsonn & Co, Rutherford, NJ). Anticoagulation was obtained using LPS-free heparin (Leoo Pharmaceutical Products, Weesp, the Netherlands; final concentration 10 U/ml blood). Wholee blood, diluted 1:1 in pyrogen-free RPMI 1640 (Bio Whittaker, Verviers, Belgium), wass stimulated for 24 h at 37°C with LPS (final concentration 10 ng/ml; from E. coli serotypee 0111:B4; Sigma, St. Louis, MO) in the presence or absence of increasing concentrationss of rhIL-10 (0.01 -1000 ng/ml; Schering-Plough). In addition, the effect of IL-100 on LPS-induced IFN-y production was studied in the presence or absence of an anti-IL-122 and/or anti-IL-18 mAb (both mouse IgG, R&D Systems, Abingdon, United Kingdom; finalfinal concentration both 10 ug/ml). The concentrations of mAbs represent at least an 1-2 logunitt excess neutralizing capacity over IL-12 and IL-18 concentrations detected after stimulation withh LPS (information on the neutralizing capacities of the mAbs used provided by the manufacturer).. Control mouse IgG (R&D Systems) was used in the appropriate concentrations. Inn separate experiments, IL-10 (10 ng/ml) was added at 0.5, 1, 2 or 4 h after the addition of LPSS to whole blood. The effect of IL-10 on IFN-y production was also studied during wholee blood stimulation with anti-CD3/anti-CD28 (1:1000; Central Laboratory of the Netherlandss Red Cross Blood Transfusion Service (CLB), Amsterdam, the Netherlands), thee superantigen Staphylococcal Enterotoxin B (SEB) (1 ug/ml; Sigma, St. Louis, MO) or PHAA (5 ug/ml; HA 16, Murex Diagnostics Ltd., Dartford, UK). After the incubation, supernatantt was obtained after centrifugation and stored at -20°C until assays were performed.
Assays s Alll measurements were done in duplicate using specific enzyme-linked immunosorbent assayss (ELISA's). Serum levels of IL-12p70 and IL-12p40 were measured as described previouslyy (19) . In short, IL-12 p70 was measured using anti-IL12 p70 mAb 20C2 as coating antibody,, biotinylated anti-IL-12 p40 mAb C8.6 as detecting antibody, and rhIL-12 as standard (detectionn limit 6 pg/ml). IL-12p40 was measured identically to the IL-12p70 ELISA using anti-IL-12p400 mAb CI 1.79 as coating antibody (detection limit 54 pg/ml). The IL-12p40 ELISAA recognizes the total amount of p40, i.e. complexed as IL-12 heterodimer or as p40 mono--or homodimer. 20C2 was kindly provided by Dr. M.K.Gately (Hoffmann La Roche Inc,, Nutley, NJ); C8.6 and CI 1.79 were kindly donated by Dr. G. Trinchieri (The Wistar Institute,, Philadelphia, PA). IL-18 was measured as described previously (Fujisaki Institute, Okayama,, Japan; detection limit 10 pg/ml) (20) . IFN-y (CLB; detection limit 2.4 pg/ml), IL-155 and IFN-y-inducible protein-10 (IP-10) (both R&D; 8.2 and 20 pg/ml respectively), and monokinee induced by IFN-y (Mig) (PharMingen, San Diego, CA; 8.2 pg/ml) were measuredd according to the instructions of the manufacturer. Levels of soluble granzyme A (GrA)) and GrB were measured by specific ELISA's exactly as described previously (21) .
Statisticall analysis
Alll data are expressed as mean SE. Changes in time were analyzed by one-way ANOVA (P-valuee vs. time). Differences between the placebo and the rhIL-10 treatment groups were analyzedd by cross-over ANOVA for repeated measures (P-value vs. placebo). Data of the in vitroo experiments were analyzed by Wilcoxon test. P < 0.05 was considered to represent a significantt difference.
Results s Effectt of IL-10 on serum levels of IFN-y and IFN-y-inducing cytokines
Administrationn of LPS induced a transient elevation of IFN-y serum concentrations peaking afterr 4-5 h (4.8 1.0 pg/ml in group 1, 12.8 7.8 pg/ml in group 2; both P < 0.05 vs. time) (Fig.. 1) . Remarkably, IL-10 administration enhanced the release of IFN-y, which was more pronouncedd for IL-10 posttreatment, resulting in peak levels of 14.4 3.6 pg/ml (group 1) andd 28.5 7.4 pg/ml (group 2) (both P <0.OOl vs. placebo). Thee production of IFN-y is regulated by a coordinated action of a number of monocyte/ macrophagee derived cytokines (22) . IL-12 is a potent inducer of IFN-y production, while IL-188 synergistically enhances IL-12 effects on IFN-y synthesis (23) (24) (25) . In addition, IL-15 andd TNF have been identified as co-stimuli for optimal IFN-y production (26, 27) . Having establishedd that IL-10 enhances LPS-induced IFN-y release in vivo, we next determined the effectt of IL-10 on IFN-y-inducing cytokines.
IL-12p700 levels remained undetectable after LPS administration in all but two volunteers.. Neither IL-10 pretreatment nor IL-10 posttreatment influenced IL-12p70 levels (dataa not shown). LPS injection resulted in a transient increase in IL-12p40 concentrations peakingg at 3 h after LPS injection (group 1:1.53 0.35 ng/ml, group 2: 1.47 0.23 ng/ml; bothh P < 0.001 vs. time) (Fig. 1) . IL-10 pre-treatment completely prevented the LPSinducedd increase of IL-12p40 levels (P < 0.001 vs. placebo), while IL-10 posttreatment onlyy partly reduced peak levels of IL-12p40 (0.83 0.13 ng/ml; NS). Serum concentrations off IL-18 were detectable prior to LPS injection (group 1: 290 68 pg/ml, group2: 234 45 pg/ml).. Administration of LPS did not result in changes in IL-18 levels in either group (data nott shown). Also, IL-10 treatment did not influence IL-18 concentrations. IL-15 levels were nott detectable before LPS administration, and remained undetectable after LPS injection withh or without IL-10 treatment. As reported previously, IL-10 pretreatment, but not posttreatment,, inhibited LPS-induced TNF release (10) . Hence, the stimulatory effect of IL-100 on IFN-y release was not associated with a detectable increase in IFN-y-inducing cytokines. . 
Effectt of IL-10 on levels of the IFN-y-dependent chemokines IP-10 and Mig
Too determine whether the IL-10-induced increase in IFN-y levels also resulted in increased IFN-yy activity, we measured serum concentrations of IP-10 and Mig, CXC chemokines of whichh the production is largely IFN-y dependent (28) . LPS injection caused a transient increasee in IP-10 peaking after 5 h (group 1: 3.47 0.88 ng/ml, group 2: 3.23 0.70 ng/ml; bothh P < 0.001 vs. time) (Fig. 2) . While IL-10 pretreatment did not affect IP-10 levels, IL-100 posttreatment resulted in enhanced IP-10 release with peak levels of 4.77 9 ng/ml (PP < 0.001 vs. placebo). LPS administration caused increased levels of Mig, which remainedd elevated until the end of the study period (12 h: group 1: 2.23 0.41 ng/ml, group 2:: 2.36 0.58 ng/ml; both P < 0.001 vs. time). IL-10 pretreatment reduced the early increasee in Mig levels between 4-6 h after LPS injection (P < 0.05 vs. placebo), while levelss at 12 h were not different. In contrast, IL-10 posttreatment resulted in increased levelss of Mig from 6 h until the end of the 12-h study period (4.45 0.74 ng/ml; P < 0.05 vs.. placebo). 
Effectt of IL-10 on levels of soluble granzymes
Wee also studied whether IL-10 treatment was associated with activation of CD8+ CTL's and/orr NK cells, as has been suggested in previous in vitro studies (13, 14) . Therefore, we measuredd serum levels of granzymes, proteins that are released from granules of activated CTLL and NK cells (29) . LPS injection induced a transient increase in serum levels of GrA, peakingg after 1.5-3 h (groupl: 30.1 4.2 pg/ml, group 2: 26.2 5.3 pg/ml; both P < 0.05 vs.. time) (Fig. 3) . IL-10 pretreatment did not influence the early rise in GrA levels, but resultedd in increased levels of GrA from 6 h after LPS until the end of the 12-h study period (PP < 0.001 vs. placebo). IL-10 posttreatment slightly delayed and increased peak levels of GrAA (28.2 2.5 pg/ml), and levels remained elevated until the end of the study period (P < 0.011 vs. placebo).
GrBB levels did not show a significant increase after LPS administration. However, both IL-100 pre-and posttreatment caused a strong increase in GrB levels, peaking after 4-6 h (groupp 1: 34. 8 4 pg/ml, group 2: 51.1 14.2 pg/ml; both P < 0.05 vs. placebo).
Effectt of IL-10 on LPS-induced production of IFN-y and IFN-y-inducing cytokines in vitro o
Inn an attempt to study the mechanisms involved in IL-10-induced enhancement of IFN-y production,, we determined the effect of IL-10 during whole blood stimulations with LPS, resultedd in a strong dose-dependent inhibition of LPS-induced IFN-y release (IL-10 1 ng/ml:: 2.8 0.4 % of IFN-y levels measured after incubation without IL-10; P < 0.05) (Fig.   4A ).. In addition, IL-10 inhibited the production of IL-12p70 and IL-18 with similar potency (bothh P< 0.05) (Fig. 4A) . Inn the in vivo experiments, the enhancement of IFN-y release occurred in the absence of detectablee changes in IL-12p70 and IL-18 levels. In whole blood in vitro, the IL-10-induced reductionn in IL-12p70 and IL-18 concentrations, which is expected to result in a strong inhibitionn of IFN-y release, could have masked a more direct stimulating effect of IL-10 on IFN-yy production. Therefore, we were interested to determine the effect of IL-10 on IFN-y productionn in whole blood in the absence of IL-12 and/or IL-18 activity. For this purpose, wee performed whole blood stimulations with LPS and IL-10 in the presence or absence of ann anti-IL-12 mAb and/or an anti-IL-18 mAb. While addition of a control Ab did not have anyy effect, addition of anti-IL-12 or anti-IL-18 resulted in a strong inhibition of IFN-y release,, which was most pronounced for anti-IL-12 ( Fig. 4B ; both P < 0.05). The combinationn of anti-IL-12 and anti-IL-18 resulted in an additional inhibitory effect (P < 0.055 vs. anti-IL-12 only). In the presence of anti-IL-12 or anti-IL-18, IL-10 still inhibited LPS-inducedd IFN-y production, although this inhibition was significantly less in the presencee of anti-IL-12 (Fig. 4C) . The inhibitory effect of IL-10 was further reduced when bothh anti-IL-12 and anti-IL-18 were added (P < 0.05).
Sincee posttreatment with IL-10 during human endotoxemia resulted in a stronger enhancementt of IFN-y release, we also studied the effect of IL-10 added at different timepointss after the start of incubation of whole blood with LPS. Addition of IL-10 at 0.5, 1,, 2 or 4 h after LPS still potently inhibited IFN-y production, although this effect was less strongg when IL-10 was added 4 h after LPS (data not shown). The inhibitory effect of IL-10 inn vitro was not specific for LPS-induced IFN-y production since IL-10 also inhibited anti-CD3/anti-CD28,, SEB-or PHA-stimulated IFN-y release (data not shown).
Discussion n
Althoughh IL-10 is considered a potent anti-inflammatory cytokine, recent studies have suggestedd that IL-10 also possesses immunostimulatory effects. The present study is the firstt to demonstrate that IL-10 exerts proinflammatory effects in humans in vivo. IL-10 treatment,, especially when administered 1 h after LPS injection, potentiated LPS-induced IFN-yy release, which was associated with elevated levels of the IFN-y-dependent chemokiness IP-10 and Mig. The stimulatory effect of IL-10 on IFN-y release was not associatedd with a detectable increase in IFN-y-indue ing cytokines. In addition, IL-10 treatmentt enhanced activation of CTL and NK cells after LPS injection as reflected by elevatedd levels of soluble GrA and GrB. The stimulatory effect of IL-10 on LPS-induced IFN-yy release could not be reproduced in whole blood in vitro, in which IL-10 dosedependentlyy reduced IFN-y production at least in part by inhibiting the synthesis of IL-12 andd IL-18. These data indicate that high dose IL-10 therapy in patients with inflammatory disorderss can be associated with undesired proinflammatory effects in vivo.
IL-100 is a potent inhibitor of the production of proinflammatory cytokines including TNF,, IL-la, IL-lp, IL-6 and IL-8 (1, 4, 9, 10 ). We here demonstrate that IL-10 stimulates thee production of the pro-inflammatory cytokine IFN-y during human endotoxemia. IFN-y iss mainly produced by CD4+ Thl cells, CD8+ T cells and NK cells (22) . IL-12 and IL-18 positivelyy regulate IFN-y production (23, 24) . IL-12 is the most potent inducer of IFN-y synthesis,, while IL-18 synergistically enhances the IL-12 effect (25, 31) . IL-12 is a heterodimericc cytokine consisting of a p35 and a p40 subunit (23) . Upon stimulation, IL12p400 is found in large excess over the biologically active IL-12p70 heterodimer. In our study,, IL-12p70 levels remained undetectable after LPS injection while IL-12p40 concentrationss transiently increased. Conceivably, LPS induces a rise in circulating IL12p700 levels only when higher doses are administered. Indeed, during severe Gramnegativee bacteremia in baboons, the plasma concentrations of both IL-12p70 and IL-12p40 increase,, albeit the former to a lesser extent (32) . In mice, IL-12p40 immunoreactivity detectedd after LPS injection comprises both p40 monomers and p40 homodimers, the latter compromisingg 20-40 % of the total p40 produced (33). To our knowledge, it has not been demonstratedd that human IL-12p40 homodimers can be detected during human endotoxemia.. On human T cell lines, IL-12p40 homodimers have been found to inhibit bindingg of IL-12 without mediating biological activity (34) . It has been found that murine IL-12p400 homodimers can function as IL-12 receptor antagonists (33, 35) , but may have immunostimulatoryy effects on CD8+ cells, resulting in IFN-y production (36) . Since IL-10 stronglyy reduced LPS-induced IL-12p40 release, it is not likely that the positive effect of IL-100 on IFN-y secretion was mediated by an effect on IL-12p40 production. Similarly, sincee IL-18 concentrations remained unchanged in all subjects, IL-10 effects on IL-18 productionn likely did not play a role. Other cytokines implicated in IFN-y production either remainedd undetectable (IL-15) or were inhibited (TNF) by IL-10 (the present study and (10)).. Together, these data suggest that the stimulatory effect of IL-10 on IFN-y production inn vivo, is mediated by other pathways or a direct effect of IL-10 on IFN-y producing cells.
Resultss from our study are in contrast with data found in previous studies in which humann volunteers were injected with increasing doses (1, 10 or 25 ug/kg) of recombinant humann IL-10 (37, 38). PBMCs, isolated at 3 h and 6 h after IL-10 administration at a dose off 10 or 25 ug/kg, produced less IFN-y during in vitro stimulation with PHA and PMA comparedd to PBMCs isolated from volunteers receiving placebo (38) . However, the inhibitoryy effect was stronger when IL-10 was administered at a dose of 10 (ig/kg, indicatingg that high dose IL-10 may not only be associated with anti-inflammatory effects. Inn this study, PHA and PMA were used as stimuli, which leads to T cell stimulation, while wee used LPS as a stimulus, which targets monocytes/macrophages. Since IFN-y is produced byy T and NK cells, and LPS has no direct effect on these cells, it could be expected that otherr stimuli could result in a similar stimulating effect. However, it seems likely that primingg of T and NK cells, either through direct or indirect stimulation, is needed for an immunostimulatoryy effect of IL-10 administration in vivo.
Previouss in vitro studies have demonstrated that IL-10 can have a direct stimulatory effectt on activated CD8+ T cells and NK cells. IL-10 enhances IL-2-stimulated proliferationn of purified human CD8+ cells (13) . Addition of IL-10 to mouse NK cells enhancess IFN-y production when they are stimulated with IL-12 and IL-18 (14) . A recent studyy showed that IL-10 enhanced the capacity of IL-18 to stimulate IFN-y production, cytotoxicityy and proliferation of murine NK cells (39) . Also, in transgenic mice expressing humann IL-10, tumor cell growth was importantly inhibited compared to tumor growth in nontransgenicc controls, an effect which was mediated in part by IL-10-activated CD8+ T cellss (40) . To determine whether IL-10 treatment during endotoxemia involves increased activationn of CD8+ T cells and NK cells in vivo, we measured concentrations of GrA and GrB.. Granzymes are a family of serine proteinases present in cytoplasmic granules of CTL andd NK cells (29, 41) , that are released upon activation and can trigger pathways of apoptosiss in the target cells (29, 42) . Measurements of levels of soluble granzymes is consideredd to reflect the involvement of CTL and NK cells in various diseases states, and increasedd plasma levels of soluble granzymes have been found in patients with reumatoid arthritis,, EBV or HIV-1 infection, and during primary cytomegalovirus infection (21, 43) . Levelss of GrA and GrB were modestly elevated after LPS administration, but IL-10 treatmentt induced a significant increase in levels of both GrA and GrB. These data suggest thatt IL-10 treatment results in enhanced activation of cytotoxic lymphocytes leading to increasedd IFN-y production.
Thee increase in IFN-y levels after IL-10 posttreatment was accompanied by enhanced releasee of IP-10 and Mig, both members of the CXC chemokine family. In vitro, IP-10 and Migg are produced by a variety of cells in response to IFN-y (28). IP-10 and Mig are closely relatedd and share a common receptor, CXCR3, which is preferentially expressed on activatedd Thl cells. IP-10 and Mig are potent chemoattractants for activated T cells and herebyy play an important role in inflammatory processes. We here report that levels of IP-100 and Mig increase during human endotoxemia, indicating that these chemokines may playy a role during systemic infection. IP-10 concentrations peaked early, while levels of Migg remained elevated until the end of the study period, indicating that these proteins are differentiallyy regulated. While IL-10 pretreatment had no effect on IP-10 levels and inhibitedd the early increase of Mig, IL-10 posttreatment enhanced both IP-10 and Mig. Sincee only IL-10 posttreatment increased IP-10 and Mig levels, while IFN-y was also increasedd with IL-10 pretreatment, these data suggest that in vivo, besides IFN-y, other factorss are involved in IP-10 and Mig production. In vitro, TNF has been shown to be a co-stimuluss for IFN-y-induced IP-10 and Mig production (44) . Previously, we have reported thatt only pretreatment with IL-10 inhibited TNF production during human endotoxemia (10),, suggesting that IL-10 posttreatment was more effective in stimulating IP-10 and Mig productionn due to enhancement of IFN-y release in the absence of a concurrent reduction in TNFF concentrations.
Thee IL-10-induced enhancement of IFN-y release in vivo could not be reproduced duringg human whole blood stimulation with LPS in vitro. In this culture system, IL-10 inducedd a strong dose-dependent inhibition of IFN-y production, which was associated with aa concurrent reduction in IL-12 and IL-18 concentrations. These findings confirm and extentt a previous study in which IL-10 was reported to attenuate IFN-y and IL-12 productionn by LPS stimulated PBMC's (45). Since we considered it possible that IFN-y releasee after low dose LPS administration to humans occurs at least in part independently fromm IL-12 and IL-18 (i.e. circulating concentrations of IL-12p70 and IL-18 remained undetectablee and unchanged respectively), we also evaluated the effect of IL-10 on LPSinducedd IFN-y release in whole blood in vitro in the absence of IL-12 and IL-18 activity. However,, in the presence of anti-IL-12 and/or anti-IL-18, IL-10 still inhibited LPS-induced IFN-yy production, although to a lesser extent, indicating that IL-10 inhibits IFN-y release in vitroo in part through inhibition of IFN-y-inducing cytokines. Hence, the effects found of IL-100 on IFN-y production in vivo likely involve cell populations or mediators, which are not presentt or present in low quantities in peripheral blood.
IL-100 is evaluated as a new adjuvant therapy for several inflammatory diseases (16, 17) .. Treatment of Crohn's disease with IL-10 has been found to be associated with a bellshapedd dose-response curve (46) . At a dose of 5-10 ug/kg s.c, IL-10 has been reported to inducee clinical remissions, but at higher dose IL-10 (20 ug/kg) the beneficial effects are lost.. In the present study we demonstrate that IL-10 used at a dose of 25 ug/kg, particularly whenn administered shortly after an inflammatory stimulus, has proinflammatory effects in humanss in vivo. Therefore, these data indicate that the potential IFN-y enhancing effect of IL-100 may especially warrant caution for the use of high dose IL-10 therapy for Thl mediatedd illnesses like Crohn's disease and rheumatoid arthritis.
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